Nahid Elyas, MD
Adolescent Medicine · Farmington Hills, MINPI 1134170384
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 103 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations.
Across 103 payments — averaging $23.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$348
- Novo Nordisk$341
- Astellas Pharma US Inc$234
- Merck$209
- Exact Sciences$169
- AstraZeneca$140
- plus $988 from 14 others
What the payments were for
- Food & beverage$2,430100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 10 | $348 |
| Novo Nordisk | 21 | $341 |
| Astellas Pharma US Inc | 8 | $234 |
| Merck | 13 | $209 |
| Exact Sciences | 5 | $169 |
| AstraZeneca | 2 | $140 |
| Abbott | 7 | $140 |
| Actelion Pharmaceuticals US, Inc. | 1 | $126 |
| Medtronic | 1 | $118 |
| Pfizer | 7 | $115 |
| Boehringer Ingelheim | 5 | $94 |
| Novartis | 6 | $85 |
| AbbVie | 4 | $81 |
| Johnson & Johnson | 4 | $61 |
| Dexcom, Inc. | 2 | $52 |
| GSK | 2 | $38 |
| Sanofi-aventis U.S. LLC | 2 | $29 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Amgen | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$244
- UPTRAVI$126
- OPSUMIT$126
- BREZTRI$125
- SYMPLICITY G3$118
- The Cologuard Plus Collection Kit$105
- MYRBETRIQ$100
How this compares
$2,430 in reported general payments places this provider in the 85th percentile of 70 adolescent medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 156 | $222,842 |
| EliquisApixaban | 216 | $222,610 |
| JanuviaSitagliptin Phosphate | 148 | $148,754 |
| TrulicityDulaglutide | 62 | $99,796 |
| JardianceEmpagliflozin | 84 | $97,409 |
| MounjaroTirzepatide | 50 | $64,961 |
| XareltoRivaroxaban | 25 | $29,918 |
| FarxigaDapagliflozin Propanediol | 21 | $27,923 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $22,823 |
| MyrbetriqMirabegron | 30 | $20,189 |
| EntrestoSacubitril/Valsartan | 16 | $19,064 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $18,620 |
| RybelsusSemaglutide | 13 | $12,252 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 79 | $12,201 |
| Atorvastatin Calcium | 1,010 | $10,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $341 | $235,094169 claims |
| PfizerEliquis | $115 | $222,610216 claims |
| MerckJanuvia, Janumet | $209 | $167,374163 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $348 | $164,757112 claims |
| Boehringer IngelheimJardiance | $94 | $97,40984 claims |
| AstraZenecaFarxiga, Symbicort, Brilinta | $140 | $46,40872 claims |
| Johnson & JohnsonXarelto | $61 | $29,91825 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $38 | $27,32537 claims |
| Astellas Pharma US IncMyrbetriq | $234 | $20,18930 claims |
| NovartisEntresto | $85 | $19,06416 claims |
| AbbVieLinzess | $81 | $9,97615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 70 adolescent medicine providers in Michigan.
Other adolescent medicine in Farmington Hills
- Bishoy ElbebawyFlint$18K
- Lisa LoweryGrand Rapids$12K
- Gursharn DosanjhGrandville$5K
- Erica HardingClarkston$5K
- Antoun OskaWarren$3K
- Ashraf BerryWarren$3K
- Jawahar TummalaFlint$2K
- Husain ArastuWarren$2K
- Robert LevyDearborn$2K
- Mohammad BitarShelby Township$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.